
Name
PRIME
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for PRIME
Name
Alternate Names
A-4942
Asta Z-4942
Cyfos#
Holoxan 1000
Ifex
Ifosfamid
Ifoxan
Iphosphamid
Iphosphamide
Iso-endoxan
Isofosfamide
Isophos-phamide
Isophosphamide
Mitoxana
MJF 9325
MJF-9325
Naxamide#
Z4942
Abbreviations
IFX
IPP
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
109724
Primary Site
Bladder
Cervical cancer
Ewing sarcoma
Head and Neck
Hodgkin lymphoma
Non-Hodgkin lymphoma
Soft tissue sarcoma, osteogenic sarcoma
Testicular cancer
Histology
None
Remarks
Antineoplastic with alkylating activity. FDA approved.
Coding
This drug should be coded
Name
Alternate Names
Ibenzmethyzin Hydrochloride
Matulane
Methylhydrazine
N-Methylhydrazine
Natulan
Natulane
Procarbazine hydrochloride
Ro-4-6467
Ro4-6467/1
Abbreviations
IBZ
MIH
PCB
PCH
PCI
PCZ
Category
Chemotherapy
Subcategory
Nonclassic alkylating agent
NSC Number
077213
77213
Primary Site
Histology
None
Remarks
An orally administered hydrazine derivative antineoplastic agent. FDA approved in stages III, IV Hodgkin's lymphoma.
Coding
This drug should be coded
Name
Alternate Names
Amethopterin
Antifolan
CL-14377
Folex
Methotrexate Sodium
Mexate
Mexate AQ
Rheumatrex
WR-19039
Abbreviations
MTX
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
740
000740
Primary Site
Bladder cancer
Breast
Gestational trophoblastic cancer
lymphoma
Meningeal leukemia
Non-Hodgkin lymphoma
Osteogenic sarcoma
Histology
None
Remarks
FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and osteosarcoma.
Coding
This drug should be coded
